2.98
+0.29(+10.78%)
Currency In USD
| Previous Close | 2.69 |
| Open | 2.78 |
| Day High | 2.98 |
| Day Low | 2.67 |
| 52-Week High | 3.39 |
| 52-Week Low | 0.78 |
| Volume | 947,262 |
| Average Volume | 895,303 |
| Market Cap | 212.5M |
| PE | -1.8 |
| EPS | -1.66 |
| Moving Average 50 Days | 2.66 |
| Moving Average 200 Days | 2.02 |
| Change | 0.29 |
If you invested $1000 in Ventyx Biosciences, Inc. (VTYX) since IPO date, it would be worth $141.77 as of September 29, 2025 at a share price of $2.98. Whereas If you bought $1000 worth of Ventyx Biosciences, Inc. (VTYX) shares 3 years ago, it would be worth $84.85 as of September 29, 2025 at a share price of $2.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases VTX3
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and ne
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
GlobeNewswire Inc.
Apr 01, 2025 11:00 AM GMT
Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: V